To Evaluate the Efficacy, Safety and Population Pharmacokinetics of GST-HG141 in Patients With Chronic Hepatitis B (CHB) Who Have an Inadequate Response to Antiviral Drug Treatment

PHASE3RecruitingINTERVENTIONAL

Enrollment

526

Participants

Timeline

Start Date

July 24, 2025

Primary Completion Date

December 1, 2026

Study Completion Date

March 1, 2027

Conditions

Chronic Hepatitis b

Interventions

DRUG

GST-HG141

GST-HG141 50 mg BID

DRUG

GST-HG141 Placebo

GST-HG141 Placebo BID

Trial Locations (1)

RECRUITING

Shulan(Hangzhou) Hospital, Hangzhou

All Listed Sponsors

lead

Fujian Akeylink Biotechnology Co., Ltd.

INDUSTRY